BIIB
BIOGEN INC.
Nasdaq: BIIB · Cambridge, MA · Healthcare
$199.10+6.48 (+3.36%)Closed
Market Cap$29.24B
Cash$2.91Bmost recent
Runwayprofitable
P/E (TTM)22.7EPS $8.79
52-Wk Range$122.68 – $204.53
Avg Volume1.5M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$199.10-11.9%
Pipeline
Drug candidates sponsored by BIOGEN · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | Blood Sample | Multiple Sclerosis | Completed | 2011-10past | 1 | |
| Phase 4 | dimethyl fumarate | Relapsing-Remitting Multiple Sclerosis+3 more | Completed | 2025-03-27past | 7 | |
| Phase 4 | natalizumab | Relapsing Multiple Sclerosis+5 more | Completed | 2025-04-30past | 9 | |
| Phase 4 | Nusinersen | Muscular Atrophy, Spinal+1 more | Completed | 2025-10-09past | 3 | |
| Phase 3 | BG9418 (interferon beta-1a) | Multiple Sclerosis | Completed | 2010-07past | 1 | |
| Phase 2 | Natalizumab (BG00002) | Multiple Sclerosis | Completed | 2012-08past | 1 | |
| Phase 3 | peginterferon beta-1a | Relapsing Multiple Sclerosis | Completed | 2015-10past | 1 | |
| Phase 3 | BIIB017 | Relapsing Multiple Sclerosis | Completed | 2015-10past | 1 | |
| Phase 3 | Midazolam | Relapsing-Remitting Multiple Sclerosis | Completed | 2016-01past | 1 | |
| Phase 3 | Aducanumab (BIIB037) | Alzheimer's Disease | Terminated | 2019-08-08past | 1 | |
| Phase 3 | Placebo | Renal Insufficiency, Chronic+3 more | Completed | 2020-11-11past | 3 | |
| Phase 3 | ALKS 8700 | Multiple Sclerosis | Completed | 2021-06-01past | 1 | |
| Phase 3 | Bardoxolone methyl | Pulmonary Hypertension+7 more | Completed | 2023-08-23past | 5 | |
| Phase 3 | BIIB074 | Trigeminal Neuralgia | Withdrawn | 2025-08-18past | 1 | |
| Phase 3 | BIIB111 | Choroideremia+1 more | Enrolling | 2026-06-04past | 1 | |
| Phase 3 | Felzartamab | Immunoglobulin A Nephropathy (IgAN)+1 more | Recruiting | 2027-05-31 | 2 | |
| Phase 3 | Litifilimab | Systemic Lupus Erythematosus (SLE) | Enrolling | 2030-03-29 | 1 | |
| Phase 3 | Zevalin (ibritumomab tiuxetan) | Non-Hodgkin's Lymphoma | Terminated | — | 1 | |
| Phase 2 | BIIB014 | Parkinson's Disease | Completed | 2009-04past | 1 | |
| Phase 1 | BG00002 (natalizumab) | Multiple Myeloma | Terminated | 2009-12past | 1 | |
| Phase 2 | Omaveloxolone Lotion 0.5% | Breast Cancer | Completed | 2015-04-30past | 1 | |
| Phase 2 | CNV1014802 | Trigeminal Neuralgia+1 more | Completed | 2016-08-16past | 3 | |
| Phase 2 | SAGE-217 | Parkinson Disease | Completed | 2017-09-11past | 1 | |
| Phase 1 | BIIB112 | X-Linked Retinitis Pigmentosa | Completed | 2020-11-18past | 1 | |
| Phase 2 | MOR202 | Glomerulonephritis+2 more | Completed | 2023-12-14past | 1 | |
| Phase 2 | BIIB131 | Ischemic Stroke | Withdrawn | 2025-07-07past | 1 | |
| Phase 1 | CNF2024 (BIIB021) | B-Cell Chronic Lymphocytic Leukemia | Terminated | 2008-07past | 1 | |
| Phase 1 | BIIB021 and Food | Advanced Solid Tumors | Completed | 2010-08past | 1 | |
| Phase 1 | CNF2024 | Tumors+2 more | Completed | 2011-04past | 2 | |
| Phase 1 | BIIB015 | Solid Tumors | Completed | 2011-06past | 1 | |
| Phase 1 | BIIB033 | Healthy | Completed | 2011-10past | 1 | |
| Phase 1 | PF-04958242 capsule | Healthy | Completed | 2012-09past | 1 | |
| Phase 1 | Test product | Healthy Volunteers | Completed | 2012-09past | 1 | |
| Phase 1 | Unnamed | Healthy+1 more | Completed | 2012-10past | 1 | |
| Phase 1 | bismuth subsalicylate (Pepto-Bismol®) | Healthy | Completed | 2013-12past | 1 | |
| Phase 1 | BIIB023 | Healthy | Completed | 2014-01past | 1 | |
| Phase 1 | RTA 408 Lotion 0.5%, 1%, 3% | Healthy | Completed | 2014-04-01past | 1 | |
| Phase 1 | PF-04958242 | Healthy | Completed | 2015-03-31past | 2 | |
| Phase 1 | [14C]-Omaveloxolone | Healthy Male Subjects | Completed | 2019-05-31past | 1 | |
| Phase 1 | Placebo oral capsule | Healthy | Completed | 2019-06-28past | 1 | |
| Phase 1 | Omaveloxolone 50 mg capsules | Hepatic Impairment | Completed | 2020-01-27past | 1 | |
| Phase 1 | BIIB076 | Alzheimer's Disease+1 more | Completed | 2020-03-03past | 1 | |
| Phase 1 | BIIB092 | Supranuclear Palsy, Progressive | Terminated | 2020-03-31past | 1 | |
| Phase 1 | BIIB054 | Parkinson's Disease | Terminated | 2021-04-23past | 1 | |
| Phase 1 | BIIB100 | Amyotrophic Lateral Sclerosis | Completed | 2021-06-21past | 1 | |
| Phase 1 | BIIB095 | Healthy Volunteers+1 more | Withdrawn | 2022-01-21past | 1 | |
| Phase 1 | BIIB104 Reference Formulation | Healthy Volunteers | Completed | 2022-01-31past | 1 | |
| Phase 1 | Aducanumab | Healthy Volunteer | Completed | 2022-07-27past | 1 | |
| Phase 1 | [14C]-BIIB091 | Healthy Volunteer | Completed | 2024-05-11past | 1 | |
| Phase 1 | BIIB091 | Healthy Volunteer | Completed | 2025-02-07past | 1 | |
| Phase 1 | omaveloxolone | Healthy+3 more | Active, not recruiting | 2025-09-30past | 5 | |
| Phase 1 | [89Zr]Zr-DFO-BIIB080 | Healthy Volunteer | Completed | 2026-03-05past | 1 | |
| Phase 1 | Tofersen | Healthy Volunteers+1 more | Recruiting | 2033-12-30 | 2 | |
| Phase 1 | Serum containing Avonex | Multiple Sclerosis | Completed | — | 1 | |
| Phase 1 | CNF1010 (17-AAG) | Chronic Lymphocytic Leukemia | Terminated | — | 1 | |
| N/A | Unnamed | Multiple Sclerosis | Completed | 2012-05past | 1 | |
| N/A | Unnamed | Progressive Multifocal Leukoencephalopathy | Terminated | 2014-08past | 1 | |
| N/A | Unnamed | Multiple Sclerosis | Completed | 2014-11past | 1 | |
| N/A | Unnamed | Relapsing-Remitting Multiple Sclerosis | Terminated | 2015-10-02past | 1 | |
| N/A | Unnamed | Relapsing-Remitting Multiple Sclerosis+2 more | Completed | 2016-02past | 1 | |
| N/A | Unnamed | Atopic Dermatitis+3 more | Completed | 2016-08past | 1 | |
| N/A | SC Peginterferon beta-1a | Multiple Sclerosis, Relapsing-Remitting | Completed | 2019-07-31past | 1 | |
| N/A | Unnamed | Choroideremia | Completed | 2021-05-07past | 1 | |
| N/A | Nusinersen Sodium Injection | Muscular Atrophy, Spinal | Active, not recruiting | 2027-02-05 | 1 | |
| N/A | Unnamed | Muscular Atrophy, Spinal | Active, not recruiting | 2027-09-02 | 1 | |
| N/A | Diroximel Fumarate | Relapsing Forms of MS+1 more | Active, not recruiting | 2032-12-01 | 2 | |
| N/A | Unnamed | Multiple Sclerosis | Completed | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.